Stock analysts at StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS – Get Rating) in a research note issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock.
RGLS has been the subject of a number of other research reports. Canaccord Genuity Group initiated coverage on Regulus Therapeutics in a research report on Tuesday, November 8th. They issued a “buy” rating and a $9.00 price target for the company. Canaccord Genuity Group assumed coverage on Regulus Therapeutics in a research report on Monday, November 7th. They set a “buy” rating and a $9.00 target price for the company. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $12.67.
Regulus Therapeutics Stock Up 1.8 %
Shares of RGLS opened at $1.66 on Monday. The business has a 50-day simple moving average of $1.72 and a two-hundred day simple moving average of $2.07. The stock has a market cap of $24.29 million, a price-to-earnings ratio of -0.75 and a beta of 1.63. Regulus Therapeutics has a 52 week low of $1.33 and a 52 week high of $4.20.
Institutional Trading of Regulus Therapeutics
About Regulus Therapeutics
Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
- Get a free copy of the StockNews.com research report on Regulus Therapeutics (RGLS)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.